|
Time course study
|
WB (6, 12, 24, and 72 h post-ROSC)
|
Sham (n = 4)
|
0
|
|
ACA (6 h, 12 h, 24 h, 72 h) (n = 16)
|
3 (1 died at 12 h, 1 died at 15 h, and 1 died at 22 h post-ROSC)
|
|
Cellular localization (24 h post-ROSC)
|
Sham (n = 1), ACA (n = 1)
|
0
|
|
Toluidine blue staining (24 h post-ROSC)
|
Sham (n = 1)
|
0
|
|
ACA (n = 1)
|
0
|
|
Short-term outcome study (up to 7-day post ROSC)
|
Fluoro-Jade C staining
|
Sham (n = 6)
|
0
|
|
ACA + vehicle (n = 6)
|
2 (1 at 24 h post-ROSC, 1 died at 48 h post-ROSC)
|
|
ACA + APC366 (50 μg) (n = 6)
|
2 (1 died at 48 h post-ROSC, 1 died at 70 h post-ROSC)
|
|
ACA + APC366 (150) (n = 6)
|
1 (died at 6 h post-ROSC)
|
|
ACA + AC55541 (30 μg) (n = 6)
|
2 (1 died on 5th day post-ROSC, 1 died on 6th post-ROSC)
|
|
Long-term outcome study (30-day post-ROSC)
|
Fluoro-Jade C staining
|
Sham (n = 6)
|
0
|
|
ACA + vehicle (n = 6)
|
0
|
|
ACA + APC366 (50 μg) (n = 6)
|
0
|
|
Mechanism study (24 h post-ROSC)
|
Western blot
|
Sham (n = 6)
|
0
|
|
ACA + vehicle (n = 6)
|
0
|
|
ACA + APC366 (50 μg) (n = 6)
|
0
|
|
ACA + AC55541 (30 μg) (n = 6)
|
0
|
|
ACA + APC366 (50 μg) + AC55541 (30 μg) (n = 6)
|
1 (died at 8 h post-ROSC)
|
|
ACA + AC55541 (30 μg) + SB203580 (300 μg) (n = 6)
|
0
|
| |
Mass spectrometry
|
APC366 (n = 1)
|
0
|
|
Total
|
120
|
109
|
11
|
